BeiGene Announces Clinical Data on Tislelizumab and Zanubrutinib to be Presented at the 24th Congress of the European Hematology Association

May 16, 2019 9:00 AM

CAMBRIDGE, Mass. and BEIJING, China, May 16, 2019 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative molecularly-targeted and immuno-oncology drugs for the treatment of cancer, today announced data presentations on its investigational anti-PD-1 antibody tislelizumab and its investigational BTK inhibitor zanubrutinib from four posters at the 24th Congress of the European Hematology Association (EHA), taking place June 13-16, 2019 in Amsterdam.

Poster Presentations:

Title:	Tislelizumab (BGB-A317) for relapsed/refractory classical Hodgkin lymphoma: updated follow-up efficacy and safety results from a Phase 2 study
Abstract Code:	PF469
Session Title:	Hodgkin lymphoma – Clinical
Date:	Friday, June 14
Time:	17:30 – 19:00 (CEST)
Lead Author:	Yuqin Song, M.D., Ph.D.

Title:	Major responses in MYD88 wildtype (MYD88WT) Waldenström Macroglobulinemia (WM) patients treated with Bruton Tyrosine Kinase (BTK) inhibitor zanubrutinib (BGB-3111)
Abstract Code:	PF487
Session Title:	Indolent and mantle-cell non-Hodgkin lymphoma – Clinical
Date:	Friday, June 14
Time:	17:30 – 19:00 (CEST)
Lead Author:	Meletios A. Dimopoulos, M.D.

Title:	Updated safety and efficacy data in a Phase 1/2 trial of patients with Waldenström Macroglobulinaemia (WM) treated with the Bruton Tyrosine Kinase (BTK) inhibitor zanubrutinib (BGB-3111)
Abstract Code:	PF481
Session Title:	Indolent and mantle-cell non-Hodgkin lymphoma – Clinical
Date:	Friday, June 14
Time:	17:30 – 19:00 (CEST)
Lead Author:	Judith Trotman, MBChB, FRACP, FRCPA

Title:	Pooled analysis of safety data from monotherapy studies of the Bruton Tyrosine Kinase (BTK) inhibitor, zanubrutinib (BGB-3111), in B-cell malignancies
Abstract Code:	PS1159
Session Title:	Chronic lymphocytic leukemia and related disorders – Clinical
Date:	Saturday, June 15
Time:	17:30 – 19:00 (CEST)
Lead Author:	Constantine S. Tam, M.D.

About BeiGene

BeiGene is a global, commercial-stage, research-based biotechnology company focused on molecularly-targeted and immuno-oncology cancer therapeutics. With a team of over 2,400 employees in China, the United States, Australia and Europe, BeiGene is advancing a pipeline consisting of novel oral small molecules and monoclonal antibodies for cancer. BeiGene is also working to create combination solutions aimed to have both a meaningful and lasting impact on cancer patients. BeiGene markets ABRAXANE^® (nanoparticle albumin-bound paclitaxel), REVLIMID^® (lenalidomide), and VIDAZA^® (azacitidine) in China under a license from Celgene Corporation.ⁱ

Investor Contact                         Media Contact
Craig West                                    Liza Heapes
+1 857-302-5189                          +1 857-302-5663
ir@beigene.com media@beigene.com

ⁱ ABRAXANE^®, REVLIMID^®, and VIDAZA^® are registered trademarks of Celgene Corporation

Source: BeiGene, LTD.